Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

FDA approves first drug for chronic yeast infection

By Brian Buntz | April 29, 2022

MycoviaThe small biopharma Mycovia Pharmaceuticals has notched its first FDA approval with Vivjoa (oteseconazole), a novel drug for treating recurrent vulvovaginal candidiasis (yeast infections).

The Durham, North Carolina-based company plans to launch the drug in the U.S. in the second quarter of the year. Vivjoa is an azole antifungal indicated for females with recurrent vulvovaginal candidiasis (RVVC) who are post-menopausal or otherwise infertile.

Specifically, the indication covers women with at least three symptomatic acute episodes of yeast infection within 12 months.

Before the approval of Vivjoya, there was no FDA-approved option for specifically treating RVVC.

Anywhere from 29% to 49% of women have had a healthcare provider-diagnosed vaginal yeast infection in their lifetime, according to an analysis in the Journal of Lower Genital Tract Disease. According to the study, at least one-fifth of the subjects suffered from recurring infections within 12 months. The analysis considered data from the U.S. and Europe.

To win approval, Mycovia submitted positive data from three Phase 3 studies.

“We believe the market need for Vivjoya is strong, and we are eager to execute our commercial plans,” said Patrick Jordan, CEO of Mycovia Pharmaceuticals, in a statement. “As we enter a new chapter of our history as a commercial biopharmaceutical company, we will continue driving our mission forward to develop novel therapies for overlooked conditions.”

In July 2021, Mycovia won a priority review of the new drug application for oteseconazole from FDA.


Filed Under: Obstetrics & gynecology
Tagged With: chronic yeast infection, FDA, Mycovia, Mycovia Pharmaceuticals, oteseconazole, Vivjoya
 

Tell Us What You Think! Cancel reply

You must be logged in to post a comment.

Related Articles Read More >

Sage and Biogen
Zuranolone could offer rapid relief from postpartum depression 
Janssen
Why Janssen’s nipocalimab could represent a ‘pipeline in a pathway’
LUCA Biologics
Is there a better way to treat UTIs? LUCA Biologics says look at the microbiome

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50